Find a Clinical Trial

Showing 11 - 20 of 37 Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Contact Number:

212-342-5162

NCT Number:

NCT04950075

Population:

Adult

Phase:

II

The purpose of this study is to learn aabout the effects of the study drug, INBRX-109 on you, your immune system, and your cancer. This study is being done to understand if INBRX-109 is effective against your chondrosarcoma and how safe this drug is. It works in a similar way as antibodies, which are proteins that are naturally present in the body. Antibodies help the body’s immune system fight diseases such as infections. INBRX-109 works by causing specific cell sensors to initiate the death of cancer cells. This is different from the ways other cancer therapies work. Are you Eligible...
PHASE 1b STUDY OF PTC596 IN COMBINATION WITH DACARBAZINE IN PATIENTS WITH LOCALLY RECURRENT, UNRESECTABLE OR METASTATIC RELAPSED/REFRACTORY LEIOMYOSARCOMA

Contact Number:

(212) 342-5162

NCT Number:

NCT03761095

Population:

Adult

Phase:

I

The purpose of this study is to evaluate the effectiveness of a new investigational drug, PTC596, used in combination with dacarbazine, for the treatment of locally recurrent, unresectable or metastatic relapsed/refractory leiomyosarcoma. The purpose of this study is to evaluate whether adding PTC596 to dacarbazine is safe, and whether the combination may work better than dacarbazine alone. Approximately 20 people will take part in this study at 1 site in the US. Are you Eligible? (Inclusion Criteria) Are you 18 years of age or older? Have you been diagnosed with unresectable or metastatic...
A Phase 1/2 Open-Label, Multicenter Study toCharacterize the Safety and Tolerability of CFT8634in Subjects With Locally Advanced or MetastaticSMARCB1-Perturbed Cancers, Including SynovialSarcoma and SMARCB1-Null Tumors

Principal Investigator:

Gary K Schwartz, MD

Contact Number:

212-342-5162

Population:

Adult

Phase:

I/II

The study drug, CFT8634, is an investigational therapy that has been shown in animal studies to help break down the BRD9 protein, an important protein in the body that helps SMARCB-null tumors, such as your own, to grow. CFT8634 is able to do so by using the body’s own protein-recycling equipment. (In short, your cells are capable of breaking down proteins into their amino acid building blocks in order to rebuild themselves again.) By breaking down the BRD9 protein, the study drug may be able to help destroy these cancer cells in humans. The purpose of this study is to find out if...
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma

Principal Investigator:

Gary K Schwartz, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT04339738

Population:

Adult

Phase:

II

The purpose of this study is to: 1. Compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone. 2. Evaluate the effect of nivolumab in combination with cabozantinib on angiosarcoma (cancer) in patients who have either received paclitaxel or similar chemotherapy previously, or whose cancer has grown previously while getting paclitaxel chemotherapy on this study. The chemotherapy drugs, paclitaxel and cabozantinib, work to prevent...
A Phase 2 Study of DS-8201a (NSC#807708, IND#153036) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma

Contact Number:

(212) 342-5162

NCT Number:

NCT04616560

Population:

Pediatrics/Adult

Phase:

II

The purpose of this study is to find out how well DS-8201a works in treating recurrent osteosarcoma (osteosarcoma that has come back after treatment) and what side effects is has on adolescents and young adults with HER2 positive recurrent osteosarcoma. The treatment involves giving DS-8201a through a vein (IV) once every 3 weeks. This 3 week time period is known as a cycle. You can receive up to 35 cycles (or about 24 months) of treatment as long as your tumor does not grow too much and you are not having any bad side effects. Are you Eligible? (Inclusion Criteria) Patients must have a...
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination with AGEN2034 (balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer

Principal Investigator:

Gary K Schwartz, MD

Contact Number:

212-342-5162

NCT Number:

NCT03860272

Population:

Adult

Phase:

I/II

This research study mainly aims to test the safety and tolerability of AGEN1181 and balstilimab and to determine the most appropriate dose of the study drug AGEN1181 alone and in combination with balstilimab. AGEN1181 targets cells that are a part of the body’s immune system to block a protein called cytotoxic T- lymphocyte associated protein-4 (CTLA-4). Balstilimab can specially block a protein called programmed-death 1 (PD-1) and prevent communication between this protein and receptors on the tumor-cells. These receptors are known to affect the body’s defense mechanism to...
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered Tcells, alone or in combination withother agents, in Participants with Advanced Tumors

Contact Number:

212-342-5162

NCT Number:

NCT04526509

Population:

Adult

Phase:

I

The purpose of this research study is to study the safety and efficacy of GSK3901961 and GSK3845097 when used to treat synovial sarcoma or non-small cell lung cancer and to examine if your tumor affects how the study drug works. You will need to receive chemotherapy for 3 to 4 days (depending on your age and your medical condition) before you are given GSK3901961 or GSK3845097. This is the first time these drugs have been used in humans. No people have ever been treated with GSK3901961 or GSK3845097. After your infusion of GSK3901961 or GSK3845097 you will be hospitalized Are you Eligible? (...
An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events due to Immune Checkpoint Blockade.

Principal Investigator:

Brian Henick, MD

Contact Number:

(212) 342-5162

NCT Number:

NCT04375228

Population:

Adult

Phase:

II

The purpose of this study is to determine the safety and effectiveness of two drugs, either rituximab or tocilizumab, in patients who develop side effects while on treatment with immunotherapy requiring prolonged steroids. Immune-related side effects are caused by activation of the immune system from treatment with immunotherapy. Both rituximab and tocilizumab have been given to patients with autoimmune diseases (diseases where the immune system is activated against normal organs). Immune-related side effects appear to closely mirror these autoimmune conditions. Are you Eligible? (Inclusion...
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT03520075

Population:

Adult

Phase:

I/II

The purpose of the study is to test the safety of the study drug, ASTX029, and to find the appropriate dose of this experimental drug to use in this and other studies. The drug that will be given to you in this study, ASTX029, is investigational. This means it has not been approved for treatment of any disease, including cancer. Are you Eligible? (Inclusion Criteria) Do you have an advanced solid tumor that is unresectable or metastatic? Is your tumor able to be biopsied? Have you not received an extracellular signal-reduced kinase (ERK) inhibitor?
A Phase 1/2a First-In-Human Study of BMS-986218 (CTL NF) A Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

Contact Number:

212-342-5162

NCT Number:

NCT03110107

Population:

Adult

Phase:

I/II

To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas. Are you Eligible? (Inclusion Criteria) Patients with advanced solid tumor Patients must be in good physical shape. This means that patients must be able to walk, care for themselves, and do light physical activities such as light housework or office work. This study is for patients age 18 or older

Find a Clinical Trial

Contact Number:

NCT Number:

Population:

Phase:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Contact Number:

NCT Number:

Population:

Phase:

Pages